Greggs acknowledged that the rising popularity of weight loss drugs is impacting its financial performance, contributing to a muted profit forecast for the coming year. The bakery chain's CEO, Roisin Currie, stated there was "no doubt" that appetite-suppressing drugs are leading consumers to seek smaller portions, affecting the company's bottom line.

Currie's comments accompanied the release of Greggs' latest financial report, which revealed lacklustre profits. While specific figures were not disclosed in conjunction with the weight loss drug impact, the company's overall performance is clearly under pressure. This comes as Greggs has been actively trying to adapt to changing consumer preferences.

The market is seeing a broader shift towards healthier eating habits, with consumers increasingly demanding products higher in protein and fibre. This trend, amplified by the use of GLP-1 drugs, is forcing food companies to re-evaluate their product offerings and portion sizes. Several firms have reported changing customer appetites as a result of these medications.

Greggs, traditionally known for its high-fat pasties, cakes, and pastries, has been attempting to diversify its menu to cater to these evolving preferences. In July, the company announced plans to target customers on weight loss drugs by introducing smaller portions and protein-rich options. This included the launch of its egg-pot, supported by the "eggs at Greggs" advertising campaign.

Looking ahead, Greggs aims to continue adapting its product line to meet the demands of health-conscious consumers, including those using weight loss medications. Currie emphasized the need to offer snack products that cater to customers on GLP-1 drugs. The company's future success hinges on its ability to navigate this changing landscape and maintain its appeal to a broader range of dietary needs.